Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 65

Sort by

Sort Order Select

Journal Articles

Eltrombopag plus diacerein vs eltrombopag in patients with ITP: a multicenter, randomized, open-label phase 2 trial

Lu Sun, Xiaoyang Huang, Juan Wang, Chenglu Yuan, Hongyu Zhao, Daqi Li, Ruirong Xu, Yan Wang, Ping Qin, Yan Shi, Jun Peng, Ming Hou, Yu Hou

Blood (2024) 144 (17): 1791–1799.

https://doi.org/10.1182/blood.2024025067

Published: 2024

Includes: Supplemental data

Journal Articles

Discovery of BT-114143, a Novel and Potent Small-Molecule Plasminogen Inhibitor for Hyperfibrinolysis

Jun Tang, Sen Ji, Xiao Hu, Yan Wang, Jun Qi, Xiao Wang, Hao Wang, Jianzong Li, Zhiqiang Li, Min Li, Shaomei Zeng, Xiong Yuan, Xiaodong Zhang

Blood (2023) 142 (Supplement 1): 1229.

https://doi.org/10.1182/blood-2023-185454

Published: 2023

Journal Articles

Patient Characteristics and Diagnostic Journey of Thrombotic Microangiopathy Associated with a Trigger: A Real-World, Retrospective, Multi-National Study

Yan Wang, Francesca Gatta, Joseph Conyers, Gregor Gibson, Kieran Wynne-Cattanach, Karl-Johan Myrén, Moh-Lim Ong

Blood (2023) 142 (Supplement 1): 5526.

https://doi.org/10.1182/blood-2023-179231

Published: 2023

Journal Articles

Real-World Analysis of the Underdiagnosis, Clinical Outcomes and Associated Burden of Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy (HSCT-TMA) in the United States of America

Yan Wang, Andrew Rava, Marlene Smuzynski, Bonny Shah, Anusorn Thanataveerat, Imad Al Dakkak, Moh-Lim Ong, Christopher C Dvorak, Vincent Ho

Blood (2023) 142 (Supplement 1): 491.

https://doi.org/10.1182/blood-2023-177671

Published: 2023

Journal Articles

Real-World Outcomes of CD19CAR T Cell Therapy in Adult Patients with Relapsed Refractory Transformed Indolent Lymphoma

Swetha Kambhampati, Reid W. Merryman, Yan Wang, Evandro Bezerra, Timothy Voorhees, Ayo S Falade, Madhav R Seshadri, Megumi Bailey, Neil Bailey, Krish Patel, Charalambos Andreadis, Adam S Kittai, Caron A Jacobson, Joycelynne Michelle Palmer, Annette Brown, Alex F. Herrera, L. Elizabeth Budde

Blood (2023) 142 (Supplement 1): 3511.

https://doi.org/10.1182/blood-2023-182467

Published: 2023

Journal Articles

Metabolomic Insights into the Pathogenesis and Prognostic Potential of Adult Acute Lymphoblastic Leukemia

Junyu Wang, Tuantuan Gui, Tong Yin, Yuting Dai, Jing Qiao, Jianfeng Li, Jie Xu, Yuanfang Liu, Yan Wang, Yun Tan, Bo Jiao, Yongmei Zhu, Zhu Chen, Wenlian Chen, Hai Fang, Jian Hou, Jian-Qing Mi, Jin Wang, Sai-Juan Chen

Blood (2023) 142 (Supplement 1): 2971.

https://doi.org/10.1182/blood-2023-184328

Published: 2023

Journal Articles

Eltrombopag Plus Diacerein Versus Eltrombopag in Adult Primary Immune Thrombocytopenia: Interim Analysis of a Multicenter, Randomized, Controlled, Phase 2 Trial

Lu Sun, Ping Qin, Ruirong Xu, Juandong Wang, Hongyu Zhao, Yan Wang, Juan Wang, Xin Wang, Yu Hou, Ming Hou

Blood (2022) 140 (Supplement 1): 8410–8411.

https://doi.org/10.1182/blood-2022-165239

Published: 2022

Journal Articles

Consolidation with Allogeneic Hematopoietic Cell Transplant Improved Survival Outcomes of Adults with Relapsed / Refractory Acute Lymphoblastic Leukemia Following Response to Memory-Enriched CD19CAR T Cells

Blood (2022) 140 (Supplement 1): 4615–4616.

https://doi.org/10.1182/blood-2022-163439

Published: 2022

Journal Articles

ASXL1 Is a Risk Factor for Thrombosis in Polycythemia Vera

Yuhui Zhang, Guangshuai Teng, Chenxiao Du, Yan Wang, Naibo Hu, Yingdi Han, Jinyu Ma, Shan Gao, Guangpeng Xiang, Zonghong Shao, Jie Bai

Blood (2022) 140 (Supplement 1): 12167–12168.

https://doi.org/10.1182/blood-2022-166476

Published: 2022

Journal Articles

Use of Plasmic Scores to Aid Diagnosis of aHUS: A Real-World Analysis of Hospitalized Patients from the Premier Healthcare Database

Christoph Gasteyger, Miguel G Uriol-Rivera, Ana I Ávila, Robert S Makar, Frank R Ernst, John N Booth III, Angels Comas, Ching Lum, Ioannis Tomazos, Yan Wang, Pavan K. Bendapudi

Blood (2022) 140 (Supplement 1): 2780–2781.

https://doi.org/10.1182/blood-2022-155843

Published: 2022

Journal Articles

A Phase 1b Study to Evaluate Safety and Efficacy of IBI188 in Combination with Azacitidine (AZA) As a First-Line Treatment in Subjects with Newly Diagnosed Higher Risk Myelodysplastic Syndrome

Blood (2022) 140 (Supplement 1): 4045–4046.

https://doi.org/10.1182/blood-2022-155901

Published: 2022

Journal Articles

Comparison of the Efficacy and Safety of Pegylated Interferon Alpha-2b and Common Interferon Alpha in Patients with Myeloproliferative Neoplasms

Guangshuai Teng, Yuhui Zhang, Chenxiao Du, Yan Wang, Naibo Hu, Yingdi Han, Jinyu Ma, Shan Gao, Guangpeng Xiang, Zonghong Shao, Jie Bai

Blood (2022) 140 (Supplement 1): 3959–3960.

https://doi.org/10.1182/blood-2022-168424

Published: 2022

Journal Articles

Clinical Significance of Prolymphocytes in Chinese Patients with Chronic Lymphocytic Leukemia

Lingxiao Xing, Yan Wang, Yi Miao, Huayuan Zhu, Jing Zhang, Li Wang, LEI Fan, Wei Xu, Jianyong Li

Blood (2021) 138 (Supplement 1): 4694.

https://doi.org/10.1182/blood-2021-149099

Published: 2021

Journal Articles

Tri-Specific CD19xCD20xCD22 VHH CAR-T Cells (LCAR-AIO) Eradicate Antigen-Heterogeneous B Cell Tumors, Enhance Expansion, and Prolong Persistence in Preclinical In Vivo Models

Zhe (joy) Zhou, Yue Han, Hong-Bo Pan, Cai-Jun Sang, Dong-Lin Shi, Chong Feng, Hui Xiao, Qiu-Chuan Zhuang, Ping-Yan Wang, Xiao-Hu (Frank) Fan

Blood (2021) 138 (Supplement 1): 1700.

https://doi.org/10.1182/blood-2021-150650

Published: 2021

Journal Articles

Real-World Patient Characteristics, Treatment Patterns and Outcomes for Patients with Atypical Hemolytic Uremic Syndrome Who Have Switched from Eculizumab to Ravulizumab in the USA

Yan Wang, Imad Al-Dakkak, Katherine Garlo, Moh-Lim Ong, Ioannis Tomazos, Arash Mahajerin

Blood (2021) 138 (Supplement 1): 5003.

https://doi.org/10.1182/blood-2021-152598

Published: 2021

Journal Articles

Targeted Therapy in CD38 + Acute Myeloid Leukemia

Naibo Hu, Chao Gao, Yuhui Zhang, Guangshuai Teng, Yan Wang, Chenxiao Du, Jie Bai

Blood (2021) 138 (Supplement 1): 4425.

https://doi.org/10.1182/blood-2021-150193

Published: 2021

Journal Articles

Venetoclax Consolidation in Patients with High-Risk CLL Who Have Been on Ibrutinib More Than a Year Achieves a High Rate of Undetectable Minimal Residual Disease

Philip A. Thompson, Yan Wang, Michael J. Keating, Alessandra Ferrajoli, Nitin Jain, Christine B. Peterson, Naveen Garg, Chongjuan Wei, Ana Ayala, Tapan M. Kadia, Prithviraj Bose, Naveen Pemmaraju, Nicholas J. Short, William G. Wierda

Blood (2021) 138 (Supplement 1): 3723.

https://doi.org/10.1182/blood-2021-149919

Published: 2021

Journal Articles

Clinical Charactistics of Ph-Negative MPN Patients with Coexistence of JAK2V617F, Calr and MPL Mutation

Dan Ma, PhD, Ping Liu, Chengyun Pan, Bingqing Cheng, Yaming Zhang, Yan Wang, Xiuying Hu, Jishi Wang, PhD

Blood (2020) 136 (Supplement 1): 27–28.

https://doi.org/10.1182/blood-2020-142096

Published: 2020

Journal Articles

The Addition of Venetoclax to Ibrutinib Achieves a High Rate of Undetectable Minimal Residual Disease in Patients with High-Risk CLL

Philip A. Thompson, MB, MS, Alessandra Ferrajoli, MD, Nitin Jain, MD, Yan Wang, Christine B Peterson, Naveen Garg, MD, Chongjuan Wei, PhD, Ana Ayala, RN, Tapan M. Kadia, MD, Prithviraj Bose, MD, Naveen Pemmaraju, MD, Nicholas J. Short, MD, Michael J. Keating, MBBS, William G. Wierda, MD PhD

Blood (2020) 136 (Supplement 1): 28–29.

https://doi.org/10.1182/blood-2020-141716

Published: 2020

Journal Articles

Triggers in Patients with Atypical Hemolytic Uremic Syndrome: An Observational Cohort Study Using a US Claims Database

Ioannis Tomazos, Katherine Garlo, Yan Wang, Peter Chen, Jeffrey Laurence, MD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136278

Published: 2020

NARROW

Eltrombopag plus diacerein vs eltrombopag in patients with ITP: a multicenter, randomized, open-label phase 2 trial

Discovery of BT-114143, a Novel and Potent Small-Molecule Plasminogen Inhibitor for Hyperfibrinolysis

Patient Characteristics and Diagnostic Journey of Thrombotic Microangiopathy Associated with a Trigger: A Real-World, Retrospective, Multi-National Study

Real-World Analysis of the Underdiagnosis, Clinical Outcomes and Associated Burden of Hematopoietic Stem Cell Transplantation-Associated Thrombotic Microangiopathy (HSCT-TMA) in the United States of America

Real-World Outcomes of CD19CAR T Cell Therapy in Adult Patients with Relapsed Refractory Transformed Indolent Lymphoma

Metabolomic Insights into the Pathogenesis and Prognostic Potential of Adult Acute Lymphoblastic Leukemia

Eltrombopag Plus Diacerein Versus Eltrombopag in Adult Primary Immune Thrombocytopenia: Interim Analysis of a Multicenter, Randomized, Controlled, Phase 2 Trial

Consolidation with Allogeneic Hematopoietic Cell Transplant Improved Survival Outcomes of Adults with Relapsed / Refractory Acute Lymphoblastic Leukemia Following Response to Memory-Enriched CD19CAR T Cells

ASXL1 Is a Risk Factor for Thrombosis in Polycythemia Vera

Use of Plasmic Scores to Aid Diagnosis of aHUS: A Real-World Analysis of Hospitalized Patients from the Premier Healthcare Database

A Phase 1b Study to Evaluate Safety and Efficacy of IBI188 in Combination with Azacitidine (AZA) As a First-Line Treatment in Subjects with Newly Diagnosed Higher Risk Myelodysplastic Syndrome

Comparison of the Efficacy and Safety of Pegylated Interferon Alpha-2b and Common Interferon Alpha in Patients with Myeloproliferative Neoplasms

Clinical Significance of Prolymphocytes in Chinese Patients with Chronic Lymphocytic Leukemia

Tri-Specific CD19xCD20xCD22 VHH CAR-T Cells (LCAR-AIO) Eradicate Antigen-Heterogeneous B Cell Tumors, Enhance Expansion, and Prolong Persistence in Preclinical In Vivo Models

Real-World Patient Characteristics, Treatment Patterns and Outcomes for Patients with Atypical Hemolytic Uremic Syndrome Who Have Switched from Eculizumab to Ravulizumab in the USA

Targeted Therapy in CD38 + Acute Myeloid Leukemia

Venetoclax Consolidation in Patients with High-Risk CLL Who Have Been on Ibrutinib More Than a Year Achieves a High Rate of Undetectable Minimal Residual Disease

Clinical Charactistics of Ph-Negative MPN Patients with Coexistence of JAK2V617F, Calr and MPL Mutation

The Addition of Venetoclax to Ibrutinib Achieves a High Rate of Undetectable Minimal Residual Disease in Patients with High-Risk CLL

Triggers in Patients with Atypical Hemolytic Uremic Syndrome: An Observational Cohort Study Using a US Claims Database

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only